IL130762A - Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia - Google Patents

Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia

Info

Publication number
IL130762A
IL130762A IL13076298A IL13076298A IL130762A IL 130762 A IL130762 A IL 130762A IL 13076298 A IL13076298 A IL 13076298A IL 13076298 A IL13076298 A IL 13076298A IL 130762 A IL130762 A IL 130762A
Authority
IL
Israel
Prior art keywords
medicaments
quinoline
manufacture
preparation
treatment
Prior art date
Application number
IL13076298A
Other languages
English (en)
Other versions
IL130762A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL130762A0 publication Critical patent/IL130762A0/xx
Publication of IL130762A publication Critical patent/IL130762A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13076298A 1997-01-11 1998-01-06 Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia IL130762A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9700504.5A GB9700504D0 (en) 1997-01-11 1997-01-11 Pharmaceutical compounds
PCT/EP1998/000143 WO1998030560A1 (fr) 1997-01-11 1998-01-06 Composes de quinoleine et de quinazoline presentant une utilite therapeutique en particulier pour le traitement de l'hyperplasie prostatique benigne

Publications (2)

Publication Number Publication Date
IL130762A0 IL130762A0 (en) 2001-01-28
IL130762A true IL130762A (en) 2005-12-18

Family

ID=10805838

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13076298A IL130762A (en) 1997-01-11 1998-01-06 Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia

Country Status (45)

Country Link
US (4) US6169093B1 (fr)
EP (1) EP0968208B1 (fr)
JP (1) JP3357677B2 (fr)
KR (1) KR100347472B1 (fr)
CN (2) CN1093858C (fr)
AP (1) AP819A (fr)
AR (1) AR010396A1 (fr)
AT (1) ATE242238T1 (fr)
AU (1) AU724990B2 (fr)
BG (1) BG63918B1 (fr)
BR (1) BR9807068A (fr)
CA (1) CA2277473C (fr)
CZ (1) CZ295580B6 (fr)
DE (1) DE69815313T2 (fr)
DK (1) DK0968208T3 (fr)
DZ (1) DZ2394A1 (fr)
EA (1) EA002851B1 (fr)
ES (1) ES2198695T3 (fr)
GB (1) GB9700504D0 (fr)
HK (1) HK1054389B (fr)
HN (1) HN1998000002A (fr)
HR (1) HRP980010B1 (fr)
HU (1) HUP0000942A3 (fr)
ID (1) ID21863A (fr)
IL (1) IL130762A (fr)
IS (1) IS2012B (fr)
MA (1) MA26465A1 (fr)
MY (1) MY119623A (fr)
NO (1) NO318609B1 (fr)
NZ (1) NZ336302A (fr)
OA (1) OA11074A (fr)
PA (1) PA8444301A1 (fr)
PE (1) PE44499A1 (fr)
PL (1) PL334678A1 (fr)
PT (1) PT968208E (fr)
SA (1) SA97180705B1 (fr)
SI (1) SI0968208T1 (fr)
SK (1) SK284779B6 (fr)
TN (1) TNSN98004A1 (fr)
TR (1) TR199901604T2 (fr)
TW (1) TW444013B (fr)
UA (1) UA62945C2 (fr)
WO (1) WO1998030560A1 (fr)
YU (1) YU31699A (fr)
ZA (1) ZA98166B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
IL141235A (en) 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
AU779118B2 (en) * 2000-03-03 2005-01-06 Pfizer Inc. 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3, 4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs
KR100602929B1 (ko) 2000-08-31 2006-07-20 에프. 호프만-라 로슈 아게 알파-1 아드레날린성 길항제로서 퀴나졸린 유도체
US6900220B2 (en) 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
CA2432578C (fr) * 2001-01-02 2008-04-01 F. Hoffmann-La Roche Ag Derives quinazolone antagonistes de recepteur alpha 1a/b adrenergique
US6734303B2 (en) 2001-05-18 2004-05-11 Pfizer Inc. Process for the production of quinazolines
GB0112061D0 (en) * 2001-05-18 2001-07-11 Pfizer Ltd Process for the production of quinazolines
GB0118752D0 (en) * 2001-08-01 2001-09-26 Pfizer Ltd Process for the production of quinazolines
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
EP1521747B1 (fr) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Modulateurs de kinase de type recepteur et procedes d'utilisation
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221582D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Method of treatment
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
MXPA05002004A (es) 2002-09-26 2005-04-28 Pfizer Derivados de pirazol.
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
EP1644343B1 (fr) * 2003-07-02 2007-07-04 F. Hoffmann-La Roche Ag Derives de quinazolinone substitues en position 5
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
EP2210607B1 (fr) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(méthyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phényl]-N'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide pour le traitement du cancer
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
WO2005089804A2 (fr) * 2004-03-16 2005-09-29 Pfizer Limited Combinaisons d'inhibiteurs de la reductase hmg-coa et d'antagonistes du recepteur adrenergique $g(a)1
AP2006003771A0 (en) 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
WO2008084493A2 (fr) * 2007-01-09 2008-07-17 Unichem Laboratories Limited Nouveau procédé de préparation de 2-halo-4-aminoquinazolines
JP2009126784A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc 2−ヨード−3,4−ジメトキシベンゾニトリルの製造方法。
JP2009126785A (ja) * 2007-11-19 2009-06-11 Mitsubishi Gas Chem Co Inc 2−ヨード−3,4−ジメトキシベンゾニトリルの製造方法
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
JP6377245B2 (ja) * 2014-03-24 2018-08-22 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Smo阻害剤としてのキノリン誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US875506A (en) * 1907-03-19 1907-12-31 Berry H Collins Guiding attachment for penholders.
GB1390014A (en) * 1971-05-07 1975-04-09 Koninklijke Pharma Fab Nv Process for the preparation of carbocyclic fused pyrimidine derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4098788A (en) * 1977-06-20 1978-07-04 Bristol-Myers Company Process for preparing quinazolines
GR79603B (fr) * 1982-07-24 1984-10-31 Pfizer
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
IT1270993B (it) * 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
GB9526546D0 (en) 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711650D0 (en) 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
CN1243513A (zh) 2000-02-02
GB9700504D0 (en) 1997-02-26
NO993396D0 (no) 1999-07-09
DE69815313T2 (de) 2003-12-11
NO993396L (no) 1999-07-09
PE44499A1 (es) 1999-05-06
SK90799A3 (en) 2001-03-12
IL130762A0 (en) 2001-01-28
US6365599B1 (en) 2002-04-02
PL334678A1 (en) 2000-03-13
ID21863A (id) 1999-08-05
ES2198695T3 (es) 2004-02-01
HUP0000942A2 (hu) 2001-04-28
AP9801175A0 (en) 1998-01-31
JP2000507966A (ja) 2000-06-27
MY119623A (en) 2005-06-30
HK1025327A1 (en) 2000-11-10
ATE242238T1 (de) 2003-06-15
CN1403453A (zh) 2003-03-19
CA2277473C (fr) 2003-08-12
CZ9902436A3 (cs) 2000-10-11
PA8444301A1 (es) 2000-05-24
OA11074A (en) 2002-03-13
SI0968208T1 (en) 2003-10-31
HRP980010B1 (en) 2002-06-30
CN1093858C (zh) 2002-11-06
WO1998030560A1 (fr) 1998-07-16
HN1998000002A (es) 1999-01-08
EP0968208B1 (fr) 2003-06-04
CA2277473A1 (fr) 1998-07-16
EA002851B1 (ru) 2002-10-31
BG103560A (en) 2000-06-30
NZ336302A (en) 2000-08-25
TNSN98004A1 (fr) 2005-03-15
PT968208E (pt) 2003-09-30
KR100347472B1 (ko) 2002-08-07
YU31699A (sh) 2001-07-10
SA97180705B1 (ar) 2005-12-26
IS5093A (is) 1999-06-25
DE69815313D1 (de) 2003-07-10
NO318609B1 (no) 2005-04-18
BR9807068A (pt) 2000-05-02
HUP0000942A3 (en) 2002-06-28
ZA98166B (en) 1999-07-09
AU724990B2 (en) 2000-10-05
BG63918B1 (bg) 2003-06-30
HK1054389B (zh) 2005-10-14
AP819A (en) 2000-04-03
AR010396A1 (es) 2000-06-07
DK0968208T3 (da) 2003-07-28
AU6208898A (en) 1998-08-03
US6653302B2 (en) 2003-11-25
TW444013B (en) 2001-07-01
CZ295580B6 (cs) 2005-08-17
TR199901604T2 (xx) 1999-12-21
US6169093B1 (en) 2001-01-02
HK1054389A1 (en) 2003-11-28
DZ2394A1 (fr) 2003-06-04
HRP980010A2 (en) 1998-10-31
KR20000070022A (ko) 2000-11-25
EP0968208A1 (fr) 2000-01-05
JP3357677B2 (ja) 2002-12-16
MA26465A1 (fr) 2004-12-20
SK284779B6 (sk) 2005-11-03
EA199900531A1 (ru) 2000-02-28
CN1191249C (zh) 2005-03-02
US20020040028A1 (en) 2002-04-04
US20030130259A1 (en) 2003-07-10
IS2012B (is) 2005-05-13
US6521629B2 (en) 2003-02-18
UA62945C2 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
SI0968208T1 (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
HUP0204226A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
IL149034A (en) Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeabiltiy reducing effect
HUP0105133A2 (hu) Kinolinszármazékok és kinazolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0204399A3 (en) Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
HUP0004286A3 (en) Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps
HUP0105114A2 (hu) Kinazolinonszármazékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás az előállításukra
CZ20011652A3 (cs) Farmaceutický přípravek zahrnující moxifloxacin, způsob výroby a použití tohoto přípravku
HUP9903732A3 (en) Use of cgmp elevators for the preparation of pharmaceutical compositions treating benign prostatic hyperplasia
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
EE04965B1 (et) Imidasoimidasoolid ja triasoolid kui p?letikuvastased hendid, nende kasutamine ravimite valmistamiseks ning farmatseutiline kompositsioon
HUP0102556A3 (en) Benzenesulfonamide-derivatives and their use as medicaments and process for the preparation of the compounds
IL155278A (en) Compressed Pyridine-4-On and Pyridine-4-On Derivatives
HUP0200309A2 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression, process for their preparation and pharmaceutical compositions containing them
IL133784A (en) Dolastatin 15 derivatives, pharmaceutical compositions comprising them and their use in medicaments for treating cancer
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
GB2343117B (en) Benzimidazole pharmaceutical composition and process of preparation
EP0799619A3 (fr) Utilisation d'antagonistes de l'adrénorécepteur alpha 1 dans la fabrication d'unmédicament pour la prévention et le traitment d'hyperplasie prostatique bénigne
PL312079A1 (en) Derivatives of 3-phenyl isoquinolin-1 (2h)-one, method of obtaining them, therapeutic agent and pharmaceutical composition
NO307930B1 (no) Benzo[f]kinolinoner, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av formulering for behandling
HUP0302913A3 (en) Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same
HUP0103832A3 (en) Triazolopyridines for the treatment of thrombosis disorders, pharmaceutical compositions containing the same and process for preparation thereof

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees